MSLN and Marinesco-Sjogren syndrome: Immune cell response, relative ‘heat’ of the tumor microenvironment, immune/inflammatory pathway activations, and genetic mutation profiles may predict the likelihood of benefit from immunotherapy in relation to MSLN expression, specifically in patients with MSS tumors.